New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies

Amarin Corporation plc (NASDAQ: AMRN) today announced two posters presented yesterday at the annual meeting of the American College of Cardiology (ACC). This research adds to the growing body of clinical and pre-clinical data relevant to the use of EPA with statins.
According to the news:

The first poster, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Patients With Elevated Cardiovascular Risk and Very High Triglyceride Levels: Results From the MARINE Study,” is an exploratory subgroup analysis of results from Amarin’s MARINE trial of Vascepa^®(icosapent ethyl) and observed that, compared to placebo in statin-treated patients with elevated cardiovascular risk and very high triglycerides (TGs), Vascepa administered at 4 g/day significantly lowered TGs and improved other parameters relevant to cardiovascular health without raising LDL (“bad”) cholesterol. The MARINE study and this subgroup analysis were led by Harold Bays, MD, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY.

Steven Ketchum, Ph.D., president of research and development and chief scientific officer at Amarin commented:

The results of these two studies add to the growing body of clinical and pre-clinical data on the effects of EPA when combined with statins under the conditions studied. Amarin’s REDUCE-IT trial, examining the effect of EPA therapy on top of statin therapy in at-risk patients with elevated triglycerides has reached target enrollment and will provide needed cardiovascular outcomes data for this important patient population.

Click here to view the full press release.